Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
Go back to Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial| (NASDAQ: BBIO) | Delayed: 67.74 +0.19 (0.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.55 | 52 Week High | $ | |||
| Open | $68.04 | 52 Week Low | $ | |||
| Day High | $68.79 | P/E | N/A | |||
| Day Low | $67.55 | EPS | $ | |||
| Volume | 3,036,099 | |||||



